🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 14 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 03/04/2023 | 315,00 | 318,00 | 313,55 | 316,33 | +0,40% | 1,41% | 835.100 |
| 31/03/2023 | 313,00 | 315,38 | 312,10 | 315,07 | +0,93% | 1,05% | 1.111.100 |
| 30/03/2023 | 314,75 | 315,56 | 310,90 | 312,16 | -0,66% | 1,48% | 781.400 |
| 29/03/2023 | 312,55 | 316,31 | 311,41 | 314,24 | +0,32% | 1,57% | 1.185.800 |
| 28/03/2023 | 310,75 | 313,33 | 309,43 | 313,25 | +1,55% | 1,26% | 1.056.700 |
| 27/03/2023 | 314,68 | 315,27 | 307,93 | 308,47 | -1,88% | 2,33% | 1.114.400 |
| 24/03/2023 | 305,38 | 315,00 | 302,87 | 314,39 | +3,16% | 3,97% | 2.376.600 |
| 23/03/2023 | 301,95 | 305,47 | 300,68 | 304,75 | +2,31% | 1,59% | 1.312.800 |
| 22/03/2023 | 303,48 | 303,99 | 297,75 | 297,87 | -1,58% | 2,06% | 774.700 |
| 21/03/2023 | 301,00 | 303,44 | 299,64 | 302,66 | +1,24% | 1,26% | 1.025.500 |
| 20/03/2023 | 296,72 | 300,74 | 296,09 | 298,95 | +1,08% | 1,57% | 767.800 |
| 17/03/2023 | 300,17 | 301,23 | 293,40 | 295,77 | -1,62% | 2,61% | 1.676.000 |
| 16/03/2023 | 291,36 | 301,55 | 290,66 | 300,64 | +2,16% | 3,74% | 1.120.700 |
| 15/03/2023 | 295,22 | 296,22 | 291,85 | 294,27 | -0,33% | 1,48% | 839.100 |
| 14/03/2023 | 293,81 | 295,56 | 290,71 | 295,25 | +0,61% | 1,65% | 1.095.200 |
| 13/03/2023 | 288,31 | 296,75 | 288,31 | 293,46 | +2,17% | 2,93% | 1.355.000 |
| 10/03/2023 | 286,58 | 296,40 | 285,92 | 287,24 | +0,13% | 3,66% | 1.459.300 |
| 09/03/2023 | 288,30 | 289,21 | 284,57 | 286,88 | +0,60% | 1,61% | 1.000.000 |
| 08/03/2023 | 285,52 | 287,11 | 283,60 | 285,18 | -0,49% | 1,23% | 676.700 |
| 07/03/2023 | 291,85 | 291,85 | 285,27 | 286,58 | -1,73% | 2,25% | 1.057.900 |
| 06/03/2023 | 290,00 | 294,00 | 288,88 | 291,62 | +0,38% | 1,77% | 1.026.400 |
| 03/03/2023 | 290,52 | 291,20 | 287,51 | 290,51 | -0,09% | 1,27% | 1.060.300 |
| 02/03/2023 | 290,10 | 293,15 | 289,57 | 290,76 | -0,16% | 1,23% | 766.600 |
| 01/03/2023 | 289,06 | 292,60 | 287,16 | 291,23 | +0,32% | 1,88% | 1.056.400 |
| 28/02/2023 | 286,22 | 291,56 | 285,60 | 290,29 | +1,01% | 2,08% | 1.510.500 |
| 27/02/2023 | 286,62 | 290,05 | 285,31 | 287,40 | +0,01% | 1,65% | 856.100 |
| 24/02/2023 | 290,40 | 291,75 | 286,48 | 287,37 | -1,78% | 1,81% | 1.085.100 |
| 23/02/2023 | 293,91 | 296,26 | 290,72 | 292,57 | -0,61% | 1,88% | 750.700 |
| 22/02/2023 | 292,84 | 296,66 | 290,00 | 294,36 | +0,64% | 2,27% | 1.010.800 |
| 21/02/2023 | 290,76 | 295,84 | 290,76 | 292,48 | -0,40% | 1,75% | 1.125.300 |